Anika Therapeutics, Inc.
ANIK
$14.88
-$0.14-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.61M | 30.62M | 27.82M | 28.22M | 26.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.61M | 30.62M | 27.82M | 28.22M | 26.17M |
| Cost of Revenue | 10.62M | 11.44M | 12.23M | 13.86M | 11.49M |
| Gross Profit | 19.00M | 19.18M | 15.58M | 14.36M | 14.68M |
| SG&A Expenses | 17.77M | 12.08M | 11.87M | 12.23M | 12.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.10M | 29.97M | 31.05M | 32.40M | 30.45M |
| Operating Income | -5.49M | 646.00K | -3.23M | -4.18M | -4.28M |
| Income Before Tax | -4.82M | 764.00K | -2.24M | -3.97M | -3.87M |
| Income Tax Expenses | 235.00K | -1.04M | 939.00K | 681.00K | 89.00K |
| Earnings from Continuing Operations | -5.06M | 1.80M | -3.18M | -4.65M | -3.96M |
| Earnings from Discontinued Operations | -- | -1.51M | 846.00K | 677.00K | -915.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.06M | 292.00K | -2.33M | -3.97M | -4.87M |
| EBIT | -5.49M | 646.00K | -3.23M | -4.18M | -4.28M |
| EBITDA | -4.08M | 1.96M | -1.83M | -2.91M | -2.69M |
| EPS Basic | -0.37 | 0.02 | -0.16 | -0.28 | -0.34 |
| Normalized Basic EPS | -0.22 | 0.03 | -0.10 | -0.17 | -0.17 |
| EPS Diluted | -0.37 | 0.02 | -0.16 | -0.28 | -0.34 |
| Normalized Diluted EPS | -0.22 | 0.03 | -0.10 | -0.17 | -0.17 |
| Average Basic Shares Outstanding | 13.53M | 14.27M | 14.42M | 14.36M | 14.30M |
| Average Diluted Shares Outstanding | 13.53M | 14.67M | 14.42M | 14.52M | 14.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |